Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nautilus Biotechnology, Inc. (NAUT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed development stage life sciences company building a single-molecule proteome analysis platform, Nautilus uses filings such as Forms 10-K, 10-Q, and 8-K to report financial results, operational updates, and other material events related to its business.
Investors reviewing NAUT filings can examine periodic reports for details on research and development and general and administrative expenses, net losses, and cash, cash equivalents, and investments, which reflect the company’s development stage profile. These filings also describe risk factors associated with Nautilus’ efforts to develop and validate its proteome analysis platform, including the scientific and technical challenges of bringing a highly novel product to market and uncertainties around timelines for validation and commercialization.
Current reports on Form 8-K are particularly relevant for tracking significant events at Nautilus. For example, the company has filed 8-Ks to furnish quarterly earnings press releases and to disclose matters such as the outcome of its annual meeting of stockholders and changes in Nasdaq listing status. One Form 8-K describes a notice from Nasdaq indicating that Nautilus had not met the minimum bid price requirement for continued listing on the Nasdaq Global Select Market and the subsequent transfer to The Nasdaq Capital Market. A later Form 8-K reports that Nautilus regained compliance with Nasdaq’s minimum bid price rule after its closing bid price met or exceeded $1.00 per share for at least ten consecutive business days.
Through this page, users can also monitor governance-related disclosures, including information about director elections and auditor ratification reported under Item 5.07 of Form 8-K. In addition, Nautilus’ filings reference its status as an emerging growth company and its use of SEC filings, press releases, webcasts, and its website as channels for disclosing material information. Stock Titan’s interface surfaces these filings with AI-powered summaries that help explain the context and key points, allowing readers to quickly understand the implications of lengthy documents such as annual reports, quarterly reports, and current reports on Form 8-K without reading every line.
Nautilus Biotechnology files its annual report describing a development-stage proteomics platform built around its Nautilus Voyager instrument and Iterative Mapping method. The company aims to measure single protein molecules at scale, targeting both broad proteome coverage and detailed proteoform analysis with high reproducibility.
Nautilus highlights a projected $57 billion proteomics market by 2030 with a 13% CAGR, and notes that about 95% of FDA-approved drug targets are proteins. It is pursuing a phased commercialization strategy, including research collaborations and an Iterative Mapping Early Access Program launched in January 2026 for Tau proteoform analysis.
Nautilus Biotechnology reported lower operating expenses and a narrower net loss for the fourth quarter and full year 2025 as it advances its single‑molecule proteomics platform toward an expected commercial launch in late 2026. Operating expenses were $15.4 million in Q4 2025, down from $20.0 million a year earlier, and $66.8 million for 2025 versus $81.5 million in 2024, reflecting reduced salaries, stock-based compensation, development costs, and in‑process R&D.
Net loss improved to $13.8 million in Q4 2025 from $17.6 million in the prior-year quarter, and to $59.0 million for 2025 from $70.8 million in 2024. Cash, cash equivalents, and investments totaled $156.1 million as of December 31, 2025, and the company believes this will fund operations through 2027.
Nautilus highlighted progress in Tau proteoform work, a new broadscale assay format, a January 2026 Iterative Mapping Early Access Program, a Michael J. Fox Foundation-supported alpha‑synuclein collaboration, and unveiling of the Nautilus Voyager™ platform, while noting it does not anticipate material 2026 revenue and expects operating expenses to rise about 15–20% year over year.
Nautilus Biotechnology (NAUT) reported an insider share purchase on a Form 4. The company’s Chief Marketing Officer bought 4,000 shares of common stock on 11/06/2025 at $1.49 per share. Following the transaction, the officer beneficially owned 4,000 shares, held directly.
Nautilus Biotechnology (NAUT) regained Nasdaq listing compliance. The company received notice on November 3, 2025 that it meets Nasdaq Listing Rule 5550(a)(2) after its common stock closed at or above $1.00 per share for a minimum of ten consecutive business days. Nasdaq stated the matter is now closed.
Earlier in 2025, NAUT had fallen below the minimum bid-price requirement and was granted compliance periods through October 28, 2025, then transferred to The Nasdaq Capital Market on October 29, 2025 with additional time to cure. Regaining compliance supports the company’s continued listing on The Nasdaq Capital Market under the NAUT ticker.
Nautilus Biotechnology (NAUT) filed its Q3 2025 10‑Q, reporting continued development-stage operations with no product revenue and a narrower quarterly loss. Net loss was $13.6 million for the quarter and $45.2 million for the nine months. Operating expenses decreased to $15.5 million in Q3, driven by lower R&D ($9.6 million) and G&A ($5.9 million), reflecting cost optimizations and prior workforce reductions.
As of September 30, 2025, the company held $131.4 million in cash, cash equivalents, and short‑term investments, and stated these resources are sufficient to fund operations for at least the next twelve months. Total assets were $200.9 million and stockholders’ equity was $169.1 million. Interest income was $1.9 million in Q3, down year over year on lower balances and yields.
Nautilus remains in the collaboration phase for its proteomics platform and expects early access offerings in the first half of 2026 (including Tau assays) with a broader launch targeted for late 2026. Shares outstanding were 126,305,122 as of October 23, 2025.
Nautilus Biotechnology, Inc. filed a current report to share that it has released its financial results for the quarter ended September 30, 2025. The company reported these results through a press release dated October 28, 2025, which is included as Exhibit 99.1.
The report explains that this earnings information is being furnished, not filed, which affects how it is treated under securities laws and future regulatory filings. The filing itself does not detail the financial figures, directing readers instead to the accompanying press release.
Nautilus Biotechnology insider purchases increased Sujal Patel's stake. The filing shows the CEO, President, Secretary and a director acquired 116,500 shares on 09/05/2025 at a weighted average price of $0.6742 and 83,500 shares on 09/08/2025 at a weighted average price of $0.683, bringing his reported direct beneficial ownership to 10,341,721 shares. The filing also discloses indirect holdings of 1,814,035 shares held in the Sujal Patel 2020 Children\'s Trust and 5,280,476 shares held by PFV I, LLC, where he is manager. The form was signed by an attorney-in-fact on 09/09/2025.
Matthew B. Murphy, listed as General Counsel and Trustee of the Murphy Family Trust, reported transactions in Nautilus Biotechnology, Inc. (NAUT) on 09/04/2025.
He purchased 20,000 shares of Nautilus common stock at $0.6429 per share and disposed of 1,250 shares on the same transaction date. After the reported purchase, the filing shows beneficial ownership of 74,140 shares held indirectly through the Murphy Family Trust.
Form 4 overview: On 06/23/2025, Nautilus Biotechnology, Inc. (ticker NAUT) granted Director Melissa B. Epperly a new equity award.
- Security type: Non-qualified stock option (right to buy common stock).
- Shares underlying option: 45,000.
- Exercise price: $0.6951 per share.
- Term: Expires 06/23/2035 (10-year life).
- Vesting schedule: Monthly vesting in 12 equal instalments, subject to Ms. Epperly maintaining “Service Provider” status, as defined in the company’s 2021 Equity Incentive Plan.
- Post-transaction beneficial ownership (derivative form): 45,000 options held directly.
The filing reports no disposals or open-market purchases of common stock; the only activity is the A-coded (grant) issuance of the option. No Rule 10b5-1 trading plan is indicated. The form was signed on 06/24/2025 by attorney-in-fact Mathew B. Murphy.
Investor takeaway: This is a routine director compensation grant that minimally affects share count but incrementally aligns the director’s incentives with shareholder value creation.